Michael Toboni, MD
Gynecologic Oncology · Birmingham, ALNPI 1750769568
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (56.2%), travel and lodging and grants — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 80.7% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2024 at $6,948 and has fallen 94.2% since, to $400 in 2025.
Across 28 payments — averaging $301.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$7K
- AstraZeneca$878
- Caris MPI, Inc.$400
- GSK$123
- Karyopharm Therapeutics Inc.$121
- Merck$95
- plus $16 from 1 others
Across 24 payments — averaging $46,757 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$870K
- Exelixis Inc.$186K
- Karyopharm Therapeutics Inc.$66K
What the payments were for
- Consulting fees$4005%
- Grants$85810%
- Travel & lodging$1,76121%
- Food & beverage$6868%
- Education$4,75056%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 19 | $6,821 |
| AstraZeneca | 2 | $878 |
| Caris MPI, Inc. | 2 | $400 |
| GSK | 1 | $123 |
| Karyopharm Therapeutics Inc. | 2 | $121 |
| Merck | 1 | $95 |
| Immunogen, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$6,626
- MI CANCER SEEK$400
- ZEJULA$123
How this compares
$8,455 in reported general payments places this provider in the 80th percentile of 27 gynecologic oncology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 11 | $6,040 |
| Gabapentin | 19 | $297 |
| Oxycodone Hcl | 38 | $285 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Birmingham
- Charles LeathBirmingham$148K
- Rebecca ArendBirmingham$70K
- Warner HuhBirmingham$59K
- David DooBirmingham$9K
- Margaret LiangBirmingham$3K
- Wesley BurkettBirmingham$3K
- Monjri ShahBirmingham$2K
- Kaitlyn DinkinsBirmingham$2K
- Christopher MayerBirmingham$1K
- Teresa BoitanoBirmingham$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.